Soleil Boughton Sells 2,503 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $13.95, for a total transaction of $34,916.85. Following the completion of the sale, the insider now directly owns 164,363 shares of the company’s stock, valued at approximately $2,292,863.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total value of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total transaction of $229,075.17.

Hims & Hers Health Trading Down 2.4 %

Hims & Hers Health stock opened at $12.38 on Thursday. The firm’s 50 day moving average price is $13.42 and its two-hundred day moving average price is $9.78. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $17.16.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same period in the prior year, the business posted ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 47.4% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HIMS. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday. SVB Leerink began coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price objective on the stock. Finally, Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.85.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HIMS. Graham Capital Management L.P. lifted its position in shares of Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after buying an additional 96,277 shares during the last quarter. Swiss National Bank lifted its stake in shares of Hims & Hers Health by 9.2% in the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after buying an additional 26,100 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after buying an additional 428,671 shares during the period. Bank of New York Mellon Corp grew its stake in Hims & Hers Health by 11.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after buying an additional 58,288 shares during the last quarter. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health in the 3rd quarter valued at $1,596,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.